Intended for healthcare professionals


Treating Shiga toxin induced haemolytic uraemic syndrome

BMJ 2012; 345 doi: (Published 19 July 2012) Cite this as: BMJ 2012;345:e4598
  1. Ferruh Artunc, associate professor
  1. 1University Hospital Tuebingen, Department of Medicine IV, Section of Nephrology and Hypertension, 72076 Tuebingen, Germany
  1. ferruh.artunc{at}

Clinical lessons from a recent outbreak of Escherichia coli O104:H4 in Germany

Shiga toxin induced haemolytic uraemic syndrome occurs in a minority of patients after infection with enterohaemorrhagic Escherichia coli or Shigella spp. It is characterised by thrombotic microangiopathy and renal failure, which are attributed to toxic effects of Shiga toxin on systemic and renal microcirculation. The pathogen is commonly part of the intestinal flora of cattle and is transmitted by contaminated food. Worldwide, the most common strain is E coli O157:H7, which causes the syndrome mainly in young children.1 Prognosis is good and treatment is mainly supportive, because no treatment has been proved to be effective and the use of antibiotics or plasmapheresis is controversial.2

In a linked research paper (doi:10.1136/bmj.e4565), Menne and colleagues present data on the effects of various treatments on the course of Shiga toxin induced haemolytic uraemic syndrome in a cohort of 298 patients treated at 23 German hospitals.3 In 2011, Germany experienced the largest reported outbreak of Shiga toxin induced haemolytic uraemic syndrome, which affected 855 of the 3842 people who had been infected with enterohaemorrhagic E coli from contaminated fenugreek …

View Full Text

Log in

Log in through your institution


* For online subscription